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Abstract
Background: We compared IGF responses of fetal and adult intestinal fibroblasts to identify a
developmental difference in the IGF-axis. Intestinal fibroblasts were isolated from maternal and
fetal jejunum. Media was conditioned at confluence and one week afterwards. The proliferative
response at confluence to 5 nM IGF-I or -II was compared.
Results: There were no significant differences in IGFBP expression at confluence. Post-confluence,
fetal fibroblasts had no significant changes in IGFBP-2 and IGFBP-3 expression. Post-confluent
maternal fibroblasts had increased IGFBP-3 levels that were significant compared to the fetal
fibroblasts. IGF-I increased in post-confluent fetal fibroblasts, while in maternal fibroblasts it
decreased (p < 0.001). IGF-II secretion decreased significantly in post-confluent maternal
fibroblasts (p < 0.05). Maternal fibroblasts proliferated more with IGF-I than IGF-II (p < 0.001). Fetal
fibroblasts responded to IGF-II slightly better than IGF-I and significantly greater than maternal cells
(p < 0.001).
Conclusion: Fetal intestinal fibroblasts respond to IGF-II with greater proliferation and do not
have the increased IGFBPs seen post-confluence in adult intestinal fibroblasts.
Background
Insulin-like growth factors are peptide growth factors and
have been found to be powerful mitogens for intestinal
epithelial cells with modulation by six specific IGF bind-
ing proteins (IGFBPs) [1,2]. The IGFBP species have been
shown to inhibit or potentiate the proliferative response
to IGFs, depending on the cell type and culture conditions
[1]. The primary IGF found in serum during prenatal
development is IGF-II [3]. IGF-II mRNA levels in the
human duodenum were also found to be five times higher
in the fetus than in the child [4].
The IGFBP-3 which is normally a negative modulator of
growth also has a developmental pattern of expression. A
study that examined 18 normal fibroblast cell lines cre-
ated from subjects ranging from fetal to 76 years of age
found progressively increasing amounts of IGFBP-3 pro-
duction with age [5]. This direct correlation of donor age
and IGFBP-3 levels was consistent during all phases of
fibroblast cell growth [5]. Fetal sheep have high circulat-
ing IGFBP-2 serum levels that peak at approximately 70%
(105 days) of gestation, then begin to fall [6]. In studies
measuring tissue specific mRNA levels, fetal tissue IGFBP-
2 follows a pattern similar to serum in fetal sheep [7].
Another study, comparing post-natal intestinal and adult
Published: 27 January 2006
BMC Developmental Biology 2006, 6:4 doi:10.1186/1471-213X-6-4
Received: 13 May 2005
Accepted: 27 January 2006
This article is available from: http://www.biomedcentral.com/1471-213X/6/4
© 2006 Corkins and Fillenwarth; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Developmental Biology 2006, 6:4 http://www.biomedcentral.com/1471-213X/6/4
Page 2 of 7
(page number not for citation purposes)
total intestinal mRNA for the IGFBPs, found higher
mRNA post-natal levels of IGFBPs-3 through 6 that fell
with age. [8].
The fibroblasts IGF axis is important in the intestine
because of the paracrine effect on the intestinal mucosa. A
dual culture model found that intestinal epithelial cells
grown on intestinal fibroblasts had greater proliferation
when stimulated by the paracrine effect of fibroblast pro-
duced IGF-II [9]. A transgenic mouse model with IGF-I
overexpression coupled with a mesenchymal promoter
was found to have increased IGF-I overexpression in the
gastrointestinal lamina propria this resulted in a mucosa
with increased DNA and protein content manifested by
increased crypt cell mitosis and sucrase activity [10].
This study was designed to compare the regulation of the
IGF-axis and the IGF responses of fetal and adult intestinal
fibroblasts. The hypothesis was that fetal small intestinal
fibroblasts would have a higher production and respond
better to IGF-II than adult intestinal fibroblasts. We also
expected to find the IGFBPs levels present to decrease to
allow increased proliferation in the fetal intestinal fibrob-
lasts.
Results
Protein assay of conditioned medium sample
The media conditioned by the cultured maternal or fetal
intestinal fibroblasts was collected at confluence and post-
confluence. The conditioned media was stored at -20°C
until analysis. The measured protein concentrations did
not vary significantly for the maternal or fetal fibroblasts
comparing confluence or post-confluence. There was also
no significant difference between maternal or fetal condi-
tioned media at either time point measured (range 1.10 to
1.16 mg/ml).
IGF-I and IGF-II expression
The conditioned media from the maternal and fetal intes-
tinal fibroblasts was assayed for IGF concentration by
radioimmunoassays. The maternal and fetal intestinal
fibroblasts produced primarily IGF-II. At confluence, the
fetal fibroblasts produced greater concentrations of IGF-I
and IGF-II than maternal fibroblasts, but this did not
achieve statistical significance (8.4 ± 1.7 vs. 5.1 ± .03 ng/
ml IGF-I, p = 0.5) (40 ± 3.0 vs. 30 ± 1.3 ng/ml IGF-II, p =
0.08).
One week post-confluent fetal fibroblasts had increased
IGF-I secretion, while that of the maternal fibroblasts
decreased (13.9 ± 0.4 versus 2.7 ± 0.3 ng/ml IGF-I, p <
0.001). The IGF-II secretion was decreased slightly one
week post-confluence in fetal fibroblasts, and it was sig-
nificantly decreased in maternal fibroblasts (29.9 ± 2.3
versus 9.5 ± 0.8 ng/mL IGF-II, p < .05). (Figure 1)
Ligand blotting for IGFBP expression
Ligand blotting utilizes the high affinity of the IGFBPs for
the IGFs to detect the presence of IGFBP species present in
the conditioned media. Three IGFBP bands were seen
consistently with relative molecular weights that have
been characterized for ovine IGFBPs-3 (42–50 kDa dou-
blet), -2 (33 kDa) and -4 (24 kDa) [7,11,12]. Immunob-
lotting was performed and verified that the 33 kDa and 24
kDa bands were IGFBP-2 and -4 respectively (data not
shown). The fibroblasts produced primarily IGFBP-2 in
both maternal and fetal cell lines. At confluence, there
were no significant differences in the expression of the
IGFBPs between the fetal and maternal fibroblasts
(IGFBP-3: fetal 114 520 ± 7 500 versus maternal 140 250
± 15 240 AIU, p = 0.147; IGFBP-2: fetal 463 130 ± 61 590
versus maternal 362 170 ± 54 830 AIU, p = 0.415; IGFBP-
4: fetal 244 360 ± 59 510 versus maternal 128 900 ± 19
710 AIU, p = 0.330).
Fetal fibroblasts had non-significant changes in expres-
sion of IGFBP-3 one-week post-confluence (114 520 ± 7
Concentrations of IGF-I and IGF-II in the conditioned media Figure 1
Concentrations of IGF-I and IGF-II in the conditioned media. 
The maternal and fetal intestinal fibroblasts produced prima-
rily IGF-II. In this representative experiment the mean and 
SEM data represents the pooled data from triplicate samples 
from the three cell lines. The fetal fibroblasts produced 
greater concentrations of IGF-I and IGF-II than maternal 
fibroblasts but did not achieve statistical significance (8.4 ± 
1.7 vs. 5.1 ± 0.03 ng/ml IGF-I, p = 0.53 and 40.3 ± 3.0 vs. 
29.99 ± 1.3 ng/ml IGF-II, p = 0.08). The one week post-con-
fluence fetal fibroblasts had increased IGF-I secretion (13.9 ± 
0.4), while that of the maternal fibroblasts decreased (2.7 ± 
0.3,* p < 0.001). The IGF-II secretion was decreased slightly 
one week post-confluence in fetal fibroblasts (29.9 ± 2.3) and 
significantly in maternal fibroblasts (to 9.5 ± 0.8, ^p < 0.05).BMC Developmental Biology 2006, 6:4 http://www.biomedcentral.com/1471-213X/6/4
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500 versus 122 170 ± 17 880 AIU, p = 0.759) and nearly
significant reductions in IGFBP-2 (463 130 ± 61 590 ver-
sus 323 940 ± 52 590 AIU, p = 0.098). In contrast, mater-
nal fibroblasts post-confluence had nearly significant
increased IGFBP-2 (362 170 ± 54 830 versus 841 450 ±
117 030 AIU, p = 0.082) and significantly increased
IGFBP-3 (140 250 ± 15 240 versus 1 123 800 ± 17 820
AIU, p = 0.002). There were no significant changes in any
of the IGFBP-4 levels measured. The increases in IGFBP-2
and IGFBP-3 in the post-confluent maternal fibroblasts
were significant when compared to the post-confluent
fetal fibroblasts (IGFBP-3: p < 0.001 and IGFBP-2: p =
0.003). (Figure 2)
Fibroblast response to IGF-I and IGF-II
Maternal and fetal fibroblasts were grown to confluence
and then treated with 5 nM recombinant human IGF-I or
IGF-II. The MTT assay demonstrated that all populations
of fibroblasts responded to IGF treatment with statistically
significant (p < 0.001) greater cell numbers. A percentage
was calculated for graphic presentation, for statistical cal-
culations the actual measured absorbance at 570 nm was
utilized. Triplicate wells of each experimental condition
was undertaken for each of the cell lines. Maternal fibrob-
lasts responded with greater cell numbers for IGF-I than
IGF-II compared to controls (88% vs 55% increase, p <
0.001). Fetal fibroblasts responded to IGF-II better than
IGF-I, although not significantly, and at the same rate that
maternal fibroblasts responded to IGF-I (88% vs 79%, p =
0.34). The amount of increase in the fetal cells in response
to IGF-II was significantly greater that the amount of
increase seen in the maternal cells (p < 0.001). (Figure 3)
Discussion
The primary finding from our studies is the increased
responsiveness of the fetal intestinal fibroblasts to IGF-II
compared to the adult intestinal fibroblasts. The adult
intestinal fibroblasts responded to IGF-II with only a 55%
increase in the cell numbers compared to controls. The
fetal intestinal fibroblasts had the maximum response to
IGF-II with an 88% increase in cell numbers. Interestingly,
this is the same rate at which the adult intestinal fibrob-
lasts responded to IGF-I. Circulating IGF-I levels are low in
fetal sheep and increase throughout gestation, while circu-
lating IGF-II and small intestine IGF-II mRNA levels are
much higher and increase to a peak late in gestation [6,7].
The primary prenatal IGF in mice and humans is IGF-II as
well, but in adults the primary circulating IGF is IGF-I
[1,3]. Therefore, our study suggests that the intestinal
fibroblast proliferation response to the IGFs is develop-
mentally regulated for the maximum response dependent
on developmental stage of the individual.
Comparing the IGF concentrations used to stimulate
fibroblast proliferation to physiologic conditions, Bloom-
field et al. reported IGF-I concentrations in sheep amni-
otic fluid of 0.25 nM at 110–112 days gestation [13]. A
paper from Blahovec et al. reported that the amniotic fluid
at 70 days gestation had concentrations that were
roughly1.28 nM IGF-I and 16.4 nM IGF-II; subsequent
western blotting for IGF-II throughout gestation showed
increasing concentrations until it peaked between 106
and 120 days gestation [14]. Studies have shown poor
absorption of enteral IGFs after birth but there are several
studies in fetal animals indicating significant absorption
of ingested IGFs [15,16]. The 5 nM concentration utilized
in these experiments correlates well with the reported IGF-
I and -II concentrations in porcine milk (ovine has not
been reported) during the immediate post-partum period
[17]. The fetal intestinal fibroblast would be expected to
be stimulated by approximately this concentration of IGFs
from both serum and luminal sources.
Both maternal and fetal intestinal fibroblasts produced
primarily IGF-II. The fetal intestinal fibroblasts main-
tained a relatively high level of IGF expression even when
post-confluent while the maternal intestinal fibroblasts
had significant decreases in IGF levels. This is consistent
with human studies which found greater levels of IGF-II
mRNA in the duodenum in fetal intestine compared with
children and adults [4]. This study also found the total
intestinal mRNA for IGF-I was higher than for IGF-II in
the adult [4]. A study characterizing the IGF production in
Ligand blot comparison of IGFBP expression Figure 2
Ligand blot comparison of IGFBP expression. Three 
IGFBP bands were seen consistently with relative molecular 
weights that have been characterized for ovine IGFBPs-3 
(42–50 kDa doublet), -2 (33 kDa) and -4 (24 kDa) [7,11,12]. 
The fibroblasts produced primarily IGFBP-2 in both maternal 
and fetal cell lines. The IGFBP levels did not significantly 
change one week post-confluence in fetal cells compared to 
maternal cells; which had a general increase in IGFBP expres-
sion.BMC Developmental Biology 2006, 6:4 http://www.biomedcentral.com/1471-213X/6/4
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a human colon fibroblast cell line and primary culture
adult small intestinal fibroblasts found significant IGF-II
and low levels of IGF-I mRNA [9]. Our cell culture data
that intestinal fibroblasts produce primarily IGF-II and
that the greatest level of production is by the fetal intesti-
nal fibroblasts is consistent with the literature mRNA
studies. The IGFBP findings were not what we hypothe-
sized. The fetal intestinal fibroblasts had no significant
changes when post-confluent. This is in comparison to the
highly significant increase in IGFBP-3 seen in the post-
confluent maternal intestinal fibroblasts. Fetal rat lung
fibroblasts plated near confluence had increased levels of
IGFBPs -2 and -3 and stable IGFBP-4 levels after 24 hours
of culture in serum-free media, similar to our conditions
[18]. An older study that examined IGFBP production by
developmental stage; found that fetal sheep skin fibrob-
lasts had relatively high levels of IGFBP production [19].
The IGFBPs produced by the fetal skin fibroblasts were
reported by relative molecular weight to be consistent
with IGFBPs -2 and -4 compared to low levels of IGFBP-3
[19]. The concentration of the IGFBP with a relative
molecular weight consistent with IGFBP-3 had a marked
increase in the perinatal period [19]. A study by Goldstein
et al that examined IGFBP-3 in 18 normal fibroblast cell
lines (skin and lung) found increasing IGFBP-3 levels that
correlated with the donors chronological age [5]. This
study found increased IGFBP-3 levels at all age levels with
increased culture time [5]. The significant increase in pro-
duction of IGFBP-3 by the maternal intestinal fibroblasts
is very consistent with the pattern seen in these other
fibroblast cell lines [5]. The lack of a significant change in
IGFBP levels in the fetal intestinal fibroblasts is in contrast
to the increased levels seen in the other studies of fetal
fibroblasts [5,18]. This lack of increase could be specu-
lated as significant finding because it would allow contin-
ued stimulation of the fetal intestinal fibroblasts by the
IGFs present.
The fetal intestinal fibroblasts are important in the devel-
opment of the intestinal mucosa. A transgenic mouse
model with a mesenchymal promoter linked to an IGF-I
gene found increased IGF-I overexpression in the gastroin-
testinal lamina propria resulted in increased crypt cell
mitosis and sucrase activity [10]. This evidence would sug-
gest a role for paracrine stimulation by the fetal intestinal
fibroblast produced IGFs on the intestinal mucosa. The
persistent production of IGFs by the fetal intestinal fibrob-
lasts suggests the developmental regulation of IGF expres-
sion for paracrine stimulation of the fetal intestinal
mucosa.
Conclusion
In this study, we always found a higher production of
both IGFs by fetal intestinal fibroblasts compared to
maternal intestinal fibroblasts. We also demonstrated
increased proliferation by fetal compared to adult intesti-
nal fibroblasts in response to IGF-II, the primary circulat-
ing IGF in the fetus.
Methods
Materials
Cell culture media, sera and reagents were obtained from
Life Technologies, Grand Island, NY. Tissue culture flasks
and six-well plates were from Falcon (Becton Dickinson,
Lincoln Park, NJ). Recombinant human [3-125I-iodoty-
rosyl] IGF-I and -II were provided by M. H. Niedenthal
(Lilly Research Laboratories, Indianapolis, IN). The IGF-II
antibody was purchased from Upstate Biotechnology
(Lake Placid, New York). BA 75 nitrocellulose was pur-
chased from Schleicher and Schuell (Keene, NH). Unless
stated, all other chemicals were obtained from Sigma (St.
Louis, MO) or Fisher (Pittsburgh, PA).
The fibroblast response to IGF-I and IGF-II Figure 3
The fibroblast response to IGF-I and IGF-II. The MTT 
assay demonstrated that all populations of fibroblasts 
responded to IGF treatment with statistically significant (p < 
0.001) greater cell numbers. In this representative experi-
ment the mean and SEM data represents the pooled data 
from duplicate samples from the three cell lines. Maternal 
fibroblasts responded with greater cell numbers for IGF-I 
than IGF-II compared to controls (88% vs 55% increase,* p < 
0.001). Fetal fibroblasts responded to IGF-II better than IGF-
I, although not significantly, and at the same rate as maternal 
fibroblasts responded to IGF-I (88% vs 79%, p = 0.34). The 
amount of increase in the fetal cells in response to IGF-II was 
significantly greater that the amount of increase seen in the 
maternal cells (^p < 0.001). Error bars are standard error of 
the mean calculated from the original absorbance data and 
divided by the mean absorbance of the controls to create a 
percent value.BMC Developmental Biology 2006, 6:4 http://www.biomedcentral.com/1471-213X/6/4
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Cell culture
The protocol was approved by the Indiana University Ani-
mal Care and Use Committee. This project utilized preg-
nant domestic farm sheep cared for in an American
Association for Laboratory Animal Care-certified facility.
Fetal sheep were delivered at 130 days gestation (85% of
term, equivalent to human 34 weeks gestation). Fetal and
maternal jejunum were harvested.
The intestine was minced and incubated in tissue culture
dishes. After 72 h, fibroblasts had migrated onto the dish
and residual tissue was removed. This is similar to a tech-
nique utilized by Fowlkes and Freeman to study sheep
skin fibroblasts [19]. Gastrointestinal epithelial and
endothelial cells do not easily grow under primary cell
culture conditions. This is the reason that there are limited
numbers of GI cell lines that are not derived from cancer
cell lines available. Fibroblasts quickly take to primary cell
culture and proliferate rapidly. After one passage, no evi-
dence of anything but fibroblasts was in evidence micro-
scopically. The primary culture fibroblasts were used with
a maximum of five passages before the studies were per-
formed. The fibroblasts were cultured in standard DMEM
media with 10% fetal bovine serum. The cells were grown
in culture to visual confluence and maintained in culture
one week past confluence. The cells at confluence and one
week post-confluence were allowed to condition serum-
free media containing 0.1% BSA for 24 hours. This media
was harvested and stored at -20°C. Three separate fetal-
maternal experiments were used to create three intestinal
fibroblast cell cultures.
Maternal and fetal fibroblasts were plated equally in 12-
well plates and grown to confluence. This time point was
chosen to evaluate the response to the IGFs while the
fibroblasts were still actively proliferating but experiments
could visually be matched at equal cell density. Micro-
scopically, the fibroblasts would continue to proliferate
until the culture plate surface was saturated with fibrob-
lasts. Six wells of each plate of the various fibroblast cell
lines were treated with control serum-free media and the
other three with 5 nM recombinant human IGF-I or IGF-
II. This dosage was utilized since it was above the minimal
dose to see a response in a previous study comparing
young and senescent fibroblasts [20]. The change in cell
numbers was compared by MTT assay after 24 hours.
Absorbance measurements were obtained from three
wells for each of the three fetal and maternal cell cultures.
These were used for significance calculations.
Protein assay
The protein content of the conditioned medium was
measured utilizing the BCA reagent according to the man-
ufacturer's guidelines (Pierce, Rockford, IL). The reaction
of protein in an alkaline environment results in the reduc-
tion of copper to a cuprous cation. The cuprous cation
reacts with the bicinchoninic acid to produce a colorimet-
ric change that is linear over a wide range. Bovine serum
albumin was utilized to create a standard curve for the
optical density at a wavelength of 570 nm with the BCA
assay. The protein concentrations of duplicate samples
from each of the three different cell lines were determined
from the standard curve.
IGF radioimmunoassay
The IGFs were extracted from the conditioned media by
aliquoting the samples into 0.8 M formic acid/0.5%
Tween 20. Acetone was added to precipitate the binding
proteins. The samples were then centrifuged at 40°C for
20 minutes. The extracted samples were incubated with
competing 125I labelled rhIGF-I or rhIGF-II (tracer) and
antibody (polyclonal rabbit anti-rhIGF-I or anti-rhIGF-II
monoclonal antibody) (Amano International Enzyme,
Troy, VA). The bound and free fractions were separated by
precipitation of the bound IGF with 10% polyethylene
glycol and a second antibody against the primary anti-
body. The greater the concentration of IGF in the sample
the lower the amount of the radioactive labelled tracer
that was bound by the antibody. Three separate culture
plates for each of the three cell lines created were ana-
lyzed. IGF concentrations of samples were estimated from
a standard curve of reference ovine IGF-I or IGF-II purified
from serum. The radioactivity in the precipitate was meas-
ured in a gamma counter and the resulting data was ana-
lyzed by a weighted four parameter logistic algorithm
[21].
Ligand blotting
Ligand blot analysis was performed as described by Hos-
senlopp et al [22] and modified by McCusker et al [23].
The media samples were electrophoresed in 12.5% poly-
acrylamide gels in the presence of 0.1% SDS under non-
reducing conditions. Following electroblotting onto 0.05
µm BA-85 nitrocellulose, the blots were probed with 125I-
IGF-II. The IGF-II binds with high affinity to the IGFBPs
separated by electrophoresis. Previous studies have dem-
onstrated that the amount of 125I-IGF-II radioactive bind-
ing is linear with the IGFBP concentrations in the
respective bands [24]. Signal intensities for radioactive
bands on each blot were quantified by use of a Phos-
phorImager (Molecular Dynamics, Sunnyvale, CA) with
the results reported as Arbitrary Intensity Units or AIUs.
Three IGFBP bands were seen consistently with relative
molecular weights that have been characterized for ovine
IGFBPs-3 (42–50 kDa doublet), -2 (33 kDa) and -4 (24
kDa) [7,11,12]. Samples from each of the separate cell
lines underwent the ligand blottingBMC Developmental Biology 2006, 6:4 http://www.biomedcentral.com/1471-213X/6/4
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Western blotting
Conditioned media samples and a conditioned media
from a human cell culture known to produce IGFBP-2 as
well standard IGFBP-4 were electrophoresed in a 15%
polyacrylamide gel in the presence of SDS under non-
reducing conditions. Following electroblotting onto
Immobilon P (Millipore, Inc., Bedford, MS), the blots
underwent western blotting with either anti-human
IGFBP-4 antibody (Austral Biologicals, San Ramon, CA)
or an anti-bovine IGFBP-2 antibody (Upstate Biotechnol-
ogy, Lake Placid, NY). The blot was labelled with 125I-pro-
tein A and exposed to film for autoradiography. The 42–
50 kDa band was assumed to be ovine IGFBP-3 based on
relative molecular weight as there is no antibody available
that reacts with ovine IGFBP-3.
MTT assay
The cell numbers were compared using the technique
described by Denizot and Lang [25]. The media is har-
vested and the cells are incubated with a solution of the
MTT (3- [4,5-dimethlythiazol-2-yl]-2,5 diphenyl tetrazo-
lium bromide) salt for 3 h at 37°C. Living cells reduce this
compound to a blue formazan product that can be meas-
ured in a spectrophotometer. There is a linear relationship
between the number of cells and the amount of the for-
mazan product produced. The MTT solution is poured off
and the plate rinsed with saline. After drying, the plate is
treated with isopropanol to dissolve the reaction product.
An aliquot is then measured for absorbance at 570 nm in
the spectrophotometer. Duplicate samples of each of the
three cell lines were analyzed.
Analysis and statistics
Values for each group are expressed as mean ± the stand-
ard error of the mean (SEM). This was calculated from the
pooled results of the duplicate or triplicate assays for each
assay (n = 6 or 9). Every experiment was performed at least
twice to confirm the results. Statistical analysis was per-
formed utilizing SigmaStat software from SPSS, Inc (Chi-
cago, IL). Analysis between two groups was done by
unpaired two-tailed Student's t-test. Analyses between
multiple groups were determined by one-way ANOVA uti-
lizing All Pairwise Multiple Comparison Procedures
(Tukey test) with 95% confidence intervals.
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